Your browser doesn't support javascript.
loading
Abdominopelvic FLASH Irradiation Improves PD-1 Immune Checkpoint Inhibition in Preclinical Models of Ovarian Cancer.
Eggold, Joshua T; Chow, Stephanie; Melemenidis, Stavros; Wang, Jinghui; Natarajan, Suchitra; Loo, Phoebe E; Manjappa, Rakesh; Viswanathan, Vignesh; Kidd, Elizabeth A; Engleman, Edgar; Dorigo, Oliver; Loo, Billy W; Rankin, Erinn B.
Afiliação
  • Eggold JT; Department of Radiation Oncology, Stanford University, Stanford, California.
  • Chow S; Cancer Biology Program, Stanford University, Stanford, California.
  • Melemenidis S; Department of Gynecologic Oncology, Stanford University, Stanford, California.
  • Wang J; Department of Radiation Oncology, Stanford University, Stanford, California.
  • Natarajan S; Department of Radiation Oncology, Stanford University, Stanford, California.
  • Loo PE; Department of Radiation Oncology, Stanford University, Stanford, California.
  • Manjappa R; Department of Radiation Oncology, Stanford University, Stanford, California.
  • Viswanathan V; Department of Radiation Oncology, Stanford University, Stanford, California.
  • Kidd EA; Department of Radiation Oncology, Stanford University, Stanford, California.
  • Engleman E; Department of Radiation Oncology, Stanford University, Stanford, California.
  • Dorigo O; Department of Pathology, Stanford University, Stanford, California.
  • Loo BW; Program in Immunology, Stanford University, Stanford, California.
  • Rankin EB; Department of Gynecologic Oncology, Stanford University, Stanford, California.
Mol Cancer Ther ; 21(2): 371-381, 2022 02.
Article em En | MEDLINE | ID: mdl-34866044
ABSTRACT
Treatment of advanced ovarian cancer using PD-1/PD-L1 immune checkpoint blockade shows promise; however, current clinical trials are limited by modest response rates. Radiotherapy has been shown to synergize with PD-1/PD-L1 blockade in some cancers but has not been utilized in advanced ovarian cancer due to toxicity associated with conventional abdominopelvic irradiation. Ultrahigh-dose rate (FLASH) irradiation has emerged as a strategy to reduce radiation-induced toxicity, however, the immunomodulatory properties of FLASH irradiation remain unknown. Here, we demonstrate that single high-dose abdominopelvic FLASH irradiation promoted intestinal regeneration and maintained tumor control in a preclinical mouse model of ovarian cancer. Reduced tumor burden in conventional and FLASH-treated mice was associated with an early decrease in intratumoral regulatory T cells and a late increase in cytolytic CD8+ T cells. Compared with conventional irradiation, FLASH irradiation increased intratumoral T-cell infiltration at early timepoints. Moreover, FLASH irradiation maintained the ability to increase intratumoral CD8+ T-cell infiltration and enhance the efficacy of αPD-1 therapy in preclinical models of ovarian cancer. These data highlight the potential for FLASH irradiation to improve the therapeutic efficacy of checkpoint inhibition in the treatment of ovarian cancer.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Receptor de Morte Celular Programada 1 Limite: Animals Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Receptor de Morte Celular Programada 1 Limite: Animals Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2022 Tipo de documento: Article